The treatment of alcoholic hepatitis remains one of the most debated topics in medicine and a fi eld of continued research. In this review, we discuss the evolution of scoring systems, including the recent development of the Glasgow alcoholic hepatitis score, role of liver biopsy and current treatment interventions. Studies of treatment interventions with glucocorticoids, pentoxifylline, infliximab, s-adenosyl-methionine, and colchicine are reviewed with discussion on quality. Glucocorticoids currently remain the mainstay of treatment for severe alcoholic hepatitis. 
in the United States [1] . Age adjusted death rate from alcohol induced liver disease accounts for 40% of deaths from cirrhosis or 28% of all deaths from liver disease [2] . Alcoholic liver disease is one of the top ten leading causes of death in developed countries, responsible for 3% (1.8 million) of all deaths [3] . While alcoholic hepatitis is common, its pathogenesis, predictors for survival, and treatment remain debated.
There have been several excellent reviews on the treatment of alcoholic hepatitis in the past year [4, 5] . The focus of our review is to expand on the treatment of alcoholic hepatitis while addressing the role of scoring systems and liver biopsy.
PATHOGENESIS
While the histology of alcoholic hepatitis is well characterized, the pathogenesis remains uncertain. A number of hepatocellular and inflammatory processes including the potential involvement of innate and adaptive immunologic responses are under investigation.
The variety of treatment options in alcoholic hepatitis share a common treatment goal of blocking the myriad of innate immunologic responses which include macrophage release of chemokines and cytokines, TNF-α, IL-1β, IL-6 and IL-8, in addition to adaptive immune responses to acetaldehyde and hydroxyethyl radical formation [6, 7] . While the immunologic responses are varied, they share similar end results of apoptosis, necrosis, infl ammation and fi brosis. The history and basis of treatment interventions in alcoholic hepatitis are centered on blocking one or more of the harmful mechanisms found in the animal model with the hope, in human trials, of providing survival benefi t (Table 1) .
SCORING SYSTEMS
There are several scoring systems applied toward predicting survival in alcoholic hepatitis. Many clinically employed scoring systems, however, are derived from related liver diseases and later validated for alcoholic hepatitis. As patient risk stratification and allocation of treatment are entirely dependent on a system to gauge short-term mortality, it is important to develop a scoring system that accurately predicts survival versus mortality.
First developed as risk stratification method for patients undergoing shunt surgery and later refined [8, 9] , the Child Turcotte Pugh (CTP), score has evolved as the
INTRODUCTION
The treatment of alcoholic hepatitis is one of the most debated topics in medicine. The prevalence of the disease, its high fatality rate, and the elusiveness of cure keeps this disease in the forefront of topic reviews and scientific investigations.
Alcoholic liver disease accounts for over 12 000 deaths per year and 300 000 years of potential life lost Table 1 Immunologic responses and directed therapies in alcoholic hepatitis most clinically used prognostic tool in cirrhotic patients. Patients are stratifi ed into three categories based on point assignment of objective and subjective measures of liver function (Appendix A). The clinical application of the CTP score applied to cirrhotic patients has been validated [10, 11] . Cited over 1700 times, the CTP score remains one of the most important clinical predicting tools in patients with cirrhosis [12] . However, in the setting of alcoholic hepatitis, there is evidence that other scoring systems may better predict survival.
The Maddrey Discriminant Function (DF) score, unlike the CTP, is derived from a clinical trial studying the effi cacy of corticosteroid therapy in patients with alcoholic hepatitis [13] . Admission prothrombin time and serum bilirubin are independently and significantly associated with mortality and serve as the key variables in calculating the DF score. Further modifi ed, in combination with the presence of encephalopathy, a DF score greater than 32 predicts greater than 50% mortality [14] . The DF score has subsequently been used to stratify patients in trials studying the efficacy of corticosteroid treatment in patients with alcoholic hepatitis [14, 15] . While the DF score provides risk stratification, concerns of center to center variability of prothrombin time measurement [16] , signifi cant mortality in patients with DF score less than 32 and low test specifi city have led some investigators to suggest alternative scoring systems [17] . The Mayo Endstage Liver Disease (MELD) Score, like the CTP score, was developed to predict survival in patients undergoing decompressive therapy for portal hypertension [18, 19] (Appendix A). Unlike the CTP score, the MELD score is derived from prospective data and lacks subjective measurements of liver function. Using a derived formula, the MELD score is calculated using prothrombin time, creatinine and bilirubin. All of which are factors Maddrey et al found to be signifi cant in his original study. However, unlike the Maddrey Discriminant Function, the MELD score is employed as a continuous assessment of liver function and includes creatinine, a marker of development of hepatorenal syndrome. It would be interesting to evaluate the Maddrey DF as a continuous marker of liver function.
The MELD score has been validated in predicting survival in patients with end-stage liver disease and chronic liver disease [19, 20] . Three retrospective studies suggest that MELD is equivalent to DF in predicting survival in patients with alcoholic hepatitis [22, 23] . One study found MELD to be more predictive of survival if calculated after the fi rst week of hospitalization [23] . This result may refl ect the fact that patients with a higher likelihood of dying decline in the fi rst few weeks of hospitalization rather than improved test sensitivity. In summary, admission MELD, DF and CPT did not differ signifi cantly from each other ( Table 2) .
Citing concerns of low specifi city of the Maddrey DF score and the diffi culty of identifying an optimal cut-off point of the MELD score [24, 25] , Forrest et al introduced the Glasgow alcoholic hepatitis score (GAHS) [16] (Appendix A). Using retrospective data from patients presenting with alcoholic liver disease, the authors use stepwise logistic regression to identify variables associated with mortality. In Table 2 , we include the results of Forrest et al.'s study with separate comparisons between GAHS versus DF and GAHS versus MELD from the validation portion of the trial. We compared the accuracies of each test via Chisquare analysis. GAHS is more accurate than DF in 28 and 84 d mortality prediction but equivalent to MELD in 28 d mortality prediction. The reported specificities of both MELD and DF in this study are quite low, especially in comparison with other studies. However, the reported low specifi city of DF signifi cantly affected its comparative predictive capacity, via chi-square analysis, against GAHS.
Alcoholic hepatitis scoring systems are in evolution. MELD and DF appear to be equivalent in predicting mortality. The higher specificity and overall accuracy of the GAHS, if confi rmed, may make it a better screening tool in the clinical trial. It would be interesting to review previous studies assessing the efficacy of glucocorticoid treatment using GAHS as the scoring system. For clinicians, however, a test with a higher sensitivity would be desirable as their primary goal is to maximize the number of patients receiving a treatment benefit. Therefore, the DF score may be preferred in the clinical setting as 
LIVER BIOPSY
Since it was repor ted first by Mallor y et al [26] the morphology of alcoholic liver disease has been well described [27] . The details and signifi cance of morphologic progression from steatosis to cirrhosis, as it relates to survival and treatment, continue to be refi ned.
Employed as part of an entry and stratifi cation criteria in a few clinical trials [13, 15, [28] [29] [30] [31] , liver biopsy for staging and predicting survival has been replaced by scoring systems. Although survival did not differ between the glucocorticoid trials that used pre-randomization biopsies versus scoring system, we think that clinical trials should enroll biopsyproven cases. Biopsy confi rmation of alcoholic hepatitis accurately defi nes the patients eligible for clinical trials and, in our view, is preferred if fever, leukocytosis and hepatic bruit are absent.
W hile histologic chang es from steatosis and steatohepatitis to cirrhosis are known, correlating degree of steatosis with liver function and survival is currently under investigation. A study by Duvoux et al [32] finds a correlation between low grade steatosis and advanced liver failure as well as lowered sensitivity to steroid treatment. However, patients with low grade steatosis had higher Maddrey discriminant function scores, which can also predict poor survivals.
The role of liver biopsy in defining prognosis and treatment of alcoholic hepatitis in the clinical setting remains unclear. A thorough patient history and physical examination has a reported sensitivity and specificity of 91% and 96% in diagnosing alcoholic hepatitis [33] . However, from the above study, four cases out of 103 were misdiagnosed as alcoholic hepatitis upon review of biopsy specimen. It is generally accepted to perform a liver biopsy if the diagnosis of alcoholic hepatitis is either in question or a concomitant pathology, such as hepatitis C, is suspected [34] . Approximately 35%-40% of alcoholics are infected with HCV [35, 36] and experience higher mortality rates than patients with alcoholic liver disease alone [37, 38] . A patient history and physical exam cannot, however, consistently distinguish between and determine the extent of alcoholic hepatitis alone versus alcoholic hepatitis with concomitant cirrhosis. A biopsy can provide useful prognostic and diagnostic information. Patients with alcoholic hepatitis and cirrhosis have signifi cantly higher 1-and 5-year mortality compared to patients with cirrhosis alone [39, 40] . Presence of perivenular fibrosis, steatosis and giant mitochondria in a known alcoholic may herald the transition from alcoholic hepatitis to cirrhosis; a transition which could be prevented with abstinence [41] [42] [43] . In clinical practice, we recommend transjugular(given the presence of coagulopathy and/or ascites) liver biopsy in cases in which it is difficult to distinguish the contribution of alcoholic hepatitis and end-stage cirrhosis, especially when the hallmarks of alcoholic hepatitis, leukocytosis, fever and hepatic bruit are absent. Since treatments are associated with complications, we believe it is prudent to be confi dent of the diagnosis before using steroids.
TREATMENT

Glucocorticoids
First studied in the treatment of alcoholic cirrhosis in [44] , the use of glucocorticoids remains perhaps the most studied and debated intervention. Reported successes of glucocorticoids are variable and appear largely dependent on the nature of the trial.
The rationale for the use of glucocorticoids is centered upon blocking the cytotoxic and inflammatory pathways in alcoholic hepatitis. Glucocorticoids decrease circulating inflammator y cytokines such as TNF-α, ICAM-1 expression, and have demonstrated short term histologic improvement in the treatment of alcoholic hepatitis [45] . It is diffi cult to provide a simple summary of results for glucocorticoid trials in alcoholic hepatitis. While all trials appeared to have been controlled, few have high quality scores given the variable defi nition of randomization and blinding in each trial [46, 47] . The trials var y by inclusion/exclusion criteria, glucocorticoid type, scoring system, length of treatment and co-interventions. The study by Mendenhall et al is particularly difficult to interpret as essentially three different intervention arms, oxandrolone, prednisolone and prednisone, are employed [48] . Lesesne et al compares prednisolone to a 1600 caloric intake diet which is below the estimated caloric needs of most hospitalized patients; his trial is not placebo controlled [49] . Furthermore, the variation in type of glucorticoid, dose, and treatment length makes it diffi cult to provide treatment guidelines for physicians.
We did a computerized search using the MEDLINE database from 1971 to August 2005 using the search headings of "steroids", "corticosteroids", "alcoholic hepatitis", "hepatitis, alcohol", "randomized" and "English". We obtained additional trials by manually searching through retrieved trials and review articles. Randomized trials including corticosteroids in the treatment of alcoholic hepatitis with the outcome measure of mortality are summarized in Table 3 . The trial results are summarized by percentage death in each group including number of patients with hepatic encephalopathy and their percentage mortality. Relative risk reduction (RRR), number needed to treat (NNT) with their associated 95% confi dence intervals are calculated for trials that reported a signifi cant benefi t in survival. Given that hepatic encephalopathy is a known predictor of mortality, we have also calculated RRR and NNT for those patients; again only in trials that reported a significant survival benefi t. We employed the Jadad score as an assessment of trial quality. The Jadad score is one of the few validated measures of randomized trial quality [46, 50, 51] . Out of a maximum score of fi ve, points are assigned based on the method of randomization, double blinding and description of withdrawals/drop-outs.
The results are variable. Five trials reported a signifi cant (71) 17/20 (85) Mendenhall et al [48] survival benefi t with glucocorticoids [13] [14] [15] 28, 49] . RRR ranged from 67% to 86%, with NNT varying between 2 and 6. As reported in the above trials and noted in our table, glucocorticoid treatment significantly reduces mortality in patients with hepatic encephalopathy. The latter trials by Carithers et al and Ramond et al, selectively treated patients with discriminant function scores greater than 32, supporting a more discriminate use of glucocorticoids [14, 15] . Of the trials which reported a non-signifi cant benefi t, there are four trials which report higher mortality in the glucocorticoid group [30, 48, 52, 53] . While glucocorticoids are relatively benign in the short term for most patients, the remaining three trials remind clinicians that there are significant complications with their use. Blitzer et al reported a higher number of fungal infections in the steroid group contributing to the greater percentage of deaths in the steroid group when compared to placebo. However, his steroid treatment group contains a higher proportion of patients with elevated total bilirubin, when compared to placebo, which may contribute to his study result [52] . Included in our discussion of nutrition in the treatment of alcoholic hepatitis, Cabre et al's study found 31% (11/35) mortality in the steroid group with 91% of deaths attributable to infection [54] . It is important to recognize the potentially serious infectious complications secondary to steroid treatment.
Subsequent meta-analyses, while still yielding conflicting results, began to delineate which patients would most benefi t from glucorticoid treatment. The fi rst meta-analysis on this topic, conducted by Imperiale and McCullough in 1990 (which antedates more recent trials), finds a protective efficacy of glucocorticoids in higher quality trials, particularly those that exclude patients with gastrointestinal bleeding but include patients with hepatic encephalopathy [55] . They found a protective efficacy of 34% overall (95% CI, 15%-48%) for patients with hepatic encephalopathy. Imperiale and McCullough's study applies quality scores which are important in the setting of such trial heterogeneity. In their paper, quality scores are assigned by independent assessors. Quality scores we use in this paper are derived from Jadad et al, and have been used in assessing the quality of randomized clinical trials [46] . We do not find a significant association between high Jadad score and trial survival benefi t. However, Jadad et al score does not consider baseline equivalence of compared groups, use of co-therapies and adequate potency of principal therapy. The variance of survival amongst the trials may have more to do with patient inclusion/ exclusion criteria and the self-derived scoring systems than trial quality and adherence to randomization and double blinding.
Meta-analysis conducted by Christensen et al, did not find an overall treatment benefit, after attempting to control for confounding variables [56] . Controlling for confounding variables without direct access to individual study data can be difficult given the heterogeneity of prior trials. A subsequent study, by Mathurin, Mendenhall, Carithers et al [57] pooled raw data from their respective trials based on DF score (greater than 200 patients with DF ≥ 32 in placebo versus steroids) and found a survival benefit. If the DF < 32, there was a > 90% survival without steroids. The conclusions from the above study provide a more defi nitive treatment guideline for clinicians. In patients with DF ≥ 32, treatment with glucocorticoids improves short ter m, 28 d, sur vival with mortality decreasing from 35% in controls to 15% with steroids.
The longer ter m benefit of glucocorticoids are diffi cult to assess given the variable long-term clinical trial defi nitions (1.5 mo, 6 mo, 1 year) [54, 48, 58] and each of the existing three trials reported different outcomes: harm, no benefi t and benefi t [54, 48, 58] . It is also diffi cult to assess longterm benefi t as alcoholic hepatitis is likely to recur unless the patient abstains.
Recommendations
A review of the literature supports a more discriminate use of glucocorticoids in patients with a Maddrey discriminant function score ≥ 32. If there is no evidence of gastrointestinal bleeding or infection, the frequent concomitant presence of hepatic encephalopathy provides an even stronger support for the use of glucocorticoids. A study by Mathurin et al suggests a simple method to identify patients who are most likely to respond to glucocorticoids. Patients with an 'early change in bilirubin levels' (ECBL), i.e. a bilirubin level at 7 d lower than the bilirubin level on the first day of treatment, were signifi cantly more likely to survive and respond to steroid treatment [59] . Discontinuation of glucocorticoid treatment in the non-responder group, i.e. patients that did not have an ECBL at 7 d, did not appear to result in adverse events [5] . Devising methods to target the patient groups most likely to benefi t are important in maximizing treatment benefi t, avoiding unnecessary complications of treatment and streamlining the treatment decision process.
Glucocorticoids, while providing a benefi t in a select group of patients, are not without risks and should be used with caution in patients with infectious complications and gastrointestinal bleeding. Further trials that are larger in sample size, involving multiple centers and with an active comparator, i.e. pentoxifylline, are needed to better delineate the true effect of glucocorticoids. Finally, as scoring systems are changing, repeat studies may be needed to reassess the treatment effect of glucocorticoids employing MELD and GAHS.
Anabolic steroids
There is a measurable and clinically apparent decline in gonandal function in patients with alcoholic liver disease [60] [61] [62] . In 1938, administration of androgens appeared to enlarge the liver of cirrhotic rats, thereby suggesting that perhaps androgens could reverse the process of fibrosis [63] . This lead to the first clinical trial where 12 patients with alcoholic cirrhosis were injected with large doses of testosterone with 'some improvement' [64] . A 2003 Cochrane systematic review could not demonstrate a significant effect of anabolic-androgenic steroids on the mortality of patients with alcoholic liver disease [65] . Three trials [48, 66, 67] included in the analysis and two trials [68, 69] excluded from the analysis are trials in which all participants have alcoholic hepatitis.
Reflective of the conclusions derived from the systematic review, Bonkovsky et al's study [67] and Mendenhall et al's 1984 study [48] did not fi nd a signifi cant survival advantage in the anabolic steroid group in the placebo. In Mendenhall et al's study, patients in the oxandrolone group were treated for 30 d. They report, however, in subgroup analysis that patients with moderate hepatitis treated with oxandrolone seemed to have survival advantage 6 mo post treatment. As the subgroup analysis did not include patients that had died within the fi rst two months of treatment, the results should be taken with some caution.
Currently, anabolic steroids are not recommended for the treatment of alcoholic hepatitis.
Pentoxifylline
Pentoxifylline is a suppressor of tumor necrosis factor alpha (TNF-α), prevents leukocyte adherence to vascular endothelium and down regulates the expression of intercellular adhesion molecule-1 in monocytes [70] . The main signaling pathway is through type 1 tumor necrosis factor receptor, TNFR1. Elevated levels of TNF-α are predictive of poor survival in alcoholic hepatitis [71, 72] . Other effects of this drug may contribute to its action such as its effects on membrane fl uidity which determine its use in peripheral vascular disease.
First studied by McHutchison et al in 1991, in patients with severe alcoholic hepatitis (defi ned as DF score ≥ 32), pentoxifylline reduced the development of hepatorenal syndrome, and as a consequence mortality, in comparison to patients who received placebo [73] . A subsequent double blind placebo controlled trial, Akriviadis et al, from the same center, supports McHutchison's findings [74] . There did not appear to be any complications as a consequence of pentoxifylline treatment. As noted by Dr. Mathurin [5] , the latter study showed no improvement in liver function tests. The reported improved survival was accounted for by a reduction in the development of hepatorenal syndrome in the treatment group. This fi nding is in sharp contrast to the glucocorticoid trials which demonstrate an improvement in liver function and in survival compared to placebo.
A small sample size, retrospective, observational study by McAvoy et al, published as an abstract, fi nds a treatment benefit with pentoxifylline only in patients stratified to GAHS ≥ 9, but not in patients with DF ≥ 32 [75] . As raw numbers are not available at press time, it is difficult to draw a meaningful conclusion from his study.
Recommendations: Pentoxifylline may reduce mortality from hepatorenal syndrome in the setting of severe alcoholic hepatitis but further studies are needed to confi rm these fi ndings. Aside from the need for head to head comparative trials with steroids, one wonders if the combination of the two treatments might exhibit an additive benefi t.
Infl iximab
Infliximab, used in the treatment of Crohn's disease, rheumatoid ar thritis and psoriasis, is a chimeric mouse/human antibody which binds to tumor necrosis alpha, blocking its effects [76] . Preliminary trial data was encouraging. Three trials reported either better survival than predicted, improved Maddrey score or laboratory parameters [76] [77] [78] . The largest and most comprehensive trial studying the efficacy of prednisone and infliximab in the treatment of alcoholic hepatitis was terminated early when a significantly higher number of deaths occurred in the treatment group [79] . The study received some criticism for its use of high dose of infl iximab and infusion protocol which varied from previous studies. In this study, investigators cited prior studies in Crohn's [80] and rheumatoid arthritis [81] in which there did not appear to be a relationship between dose of infl iximab and rate of infection [82] . Furthermore, Dr. Naveau contends, perhaps infl iximab is not the TNF-α blocking agent for alcoholic hepatitis (Table 4 ).
An open label uncontrolled pilot study on etanercept in the treatment of moderate to severe alcoholic hepatitis was completed [83] . Of the 13 patients treated, 7 had Maddrey DF greater than 32 and two of the seven died within 32 d. Etanercept was discontinued in 3 patients secondary to infection, hepatorenal decompensation and gastrointestinal bleeding. Therefore, there is no particular evidence one way or the other to suggest a benefi cial or detrimental effect of treatment. As etanercept targets soluble TNF, whereas infl iximab targets both soluble and [78] 2003
Case Series 10 Infl iximab 5 mg/kg times one 72 h assessment Signifi cant reduction in laboratory parameters Increased hepatic and renal blood fl ow Naveau et al [79] 2004 Randomized 36 All patients: Prednisone for 28 d R1: Infl iximab 10 mg/kg R2: Placebo
Signifi cantly higher rate of infections in treated group Non-signifi cantly higher rate of death in treated group Study stopped secondary to adverse events in treatment group membrane bound TNF, it is uncertain what the advantages/ disadvantages are of this distinction in the setting of this specifi c disease target. Infliximab is not currently recommended for the treatment of alcoholic hepatitis, outside of clinical trials. Although concerns have been raised about increased risk of infection, the more disturbing aspect has been recent warnings of acute liver failure in patients with Crohn's disease and rheumatoid arthritis treated with infl iximab [84] . This risk may preclude its use in patients with underlying severe liver injury who are less capable of withstanding an additional insult to the liver.
Nutrition
There are multiple etiologies for weight loss and malnutrition in patients with years of alcohol abuse. Weight loss can be refl ective of years of substitution of alcohol for more than 50% of other calories [85] , malabsorption of dietary fat and nutrients [86] and the induction of a catabolic state resulting in skeletal muscle depletion [87] . Recently reviewed [4] parenteral and enteral nutrition, while improving liver function in a few studies in alcoholic hepatitis [88] [89] [90] has yet to demonstrate a change in clinical outcome.
Mendenhall et al have done the most extensive assessment on the effect of protein calorie malnutrition (PCM) and protein energy malnutrition (PEM) on survival and liver function. The results of their interventional studies are shown in Table 5 . The observed associations between degree of malnutrition, as calculated by PCM or PEM score, and severity of liver disease [91] [92] [93] as well as improvement of survival with improved PCM score [94] serve as the basis for determining the effect of nutritional intervention on survival and liver function in alcoholic hepatitis [69, 95] . Nutritional interventions such as caloric amount, type, mode and duration of supplementation vary among the trials. For example, the 1600 caloric nutritional intervention in Lesesne et al's study is below that of most hospitalized patients. A positive correlation between nutritional intake and survival, if present, would not be expected. Much as in the case of the glucocorticoid literature, it would be difficult to provide clinical recommendations when the treatment interventions and outcomes vary. Furthermore, it is diffi cult to draw meaningful clinical conclusions. While nitrogen balance improves in the nutrition intervention arm, survival remains unchanged.
The majority of trials did not fi nd a survival advantage in nutritional support. There are two trials which showed a survival advantage. Nasrallah et al's study is smaller and both groups receive a 3000 kCal diet with protein, which is an intervention treatment in some studies. Mendenhall et al, found a later survival advantage, 6 mo post treatment, in the moderately malnourished group. This is in contrast to Mezey et al's study which did not find a survival advantage up to two years after treatment.
Recommendations: It is important to assess nutritional status of patients in order to recognize and treat the distinct nutritional deficiencies inherent in alcoholic cirrhosis and hepatitis. At this time, however, nutritional supplementation during acute presentation of alcoholic hepatitis does not appear to affect survival.
Colchicine
The final histologic stage in alcoholic liver disease is cirrhosis. Found to inhibit liver fibrosis in rats [96] , colchicine's anti-fibrotic activity presented a theoretical possibility of preventing liver fi brosis in humans.
Three clinical trials in the setting of alcoholic hepatitis [97, 98] and a Cochrane database review in the setting of alcoholic and non-alcoholic liver fi brosis [99] fail to find a benefit in the treatment of alcoholic hepatitis with colchicine. Recently published and not included in the cochrane review, the largest trial studying long-term colchicine in the setting of alcoholic cirrhosis did not fi nd a therapeutic benefi t when compared to placebo, in concordance with prior literature [100] . Colchicine is not currently recommended for the treatment of alcoholic hepatitis.
S-adenosyl-methionine
SAMe, produced from methionine by adenosylmethionine synthetase, is important in the metabolism of nucleic acids, structure and function of cell membranes and as a precursor of glutathione. Glutathione may be protective in alcohol induced liver injury [101] . However, in liver disease there is an impairment of enzyme activation of methionine which cannot be corrected by methionine supplementation [102] . In the setting of alcoholic hepatitis, there is a measurable decrease in hepatic methionine, SAMe and glutathione levels [103] . In animal studies, administration of SAMe increased glutathione levels, attenuated ethanol induced liver injury as well as liver injury caused by other hepatotoxins [104] [105] [106] [107] . In a 2001 Cochrane systematic review [108] , SAMe has yet to consistently demonstrate a signifi cant benefi cial effect on the mortality in the setting of alcoholic liver disease. None of the analyzed trials in the systematic review targeted patients with alcoholic hepatitis. The largest multicenter and highest Jadad quality scoring trial, by Mato et al, treated patients with alcoholic cirrhosis with SAMe for up to two years [109] . There was an overall decline in mortality in the treatment group compared to placebo, but did not reach signifi cance. Excluding patients with Child's C cirrhosis, however, did yield a signifi cant mortality benefi t.
There are currently two NIH funded trials studying the effect of SAMe on the mortality in the setting of alcoholic cirrhosis. There has yet to be a trial studying the effect of SAMe administration on survival in the setting of acute alcoholic hepatitis.
SAMe is currently not recommended in the treatment of acute alcoholic hepatitis.
Propylthiouracil (PTU)
Found to reduce hypoxic hepatocellular injury in ethanol fed rats [110] , subsequent animal studies confirm PTU's protective role against oxidative and ischemic liver injury [111] ; similar hepatic injuries are found in patients with alcoholic hepatitis [112] . In a 2001 Cochrane systematic review [113] , PTU did not provide a signifi cant survival benefi t in the setting of alcoholic liver disease. All of the analyzed six studies (3 of which were published only in abstract) included patients with alcoholic hepatitis [111, [114] [115] [116] [117] [118] . Contrar y to animal studies, hepatic histologic improvement with PTU administration is not replicated in clinical trial literature. PTU also does not appear to have a measurable effect on splanchnic hemodynamics in the setting of alcoholic cirrhosis [119] . While the systematic review did not fi nd a signifi cant association between PTU and adverse events, one trial was discontinued when higher mortality rates were observed in the PTU group [111] . Furthermore, there are case reports and several reviews on fulminant hepatic failure and hepatitis [120] [121] [122] [123] [124] secondary to PTU in addition to leukopenia [125] Propylthiouracil is not recommended for the treatment of alcoholic hepatitis.
CONCLUSIONS
The treatment of alcoholic hepatitis continues to evolve as our understanding of the disease process expands. As it does so, however, it is important that our clinical trials attempt to achieve the highest quality possible. Trials Lesesne et al [49] 1978 Randomized 14 patients, alcoholic hepatitis and encephalopathy 7 controls, 1600 Kcal diet Reduction in mortality in the prednisolone arm 7 study, prednisolone
Galambos et al [129] 1979
Case series 11 patients, alcoholic hepatitis 4, enteral hyperalimentation No difference in mortality 7, parenteral hyperalimentation Increased nitrogen balance in study group Nasrallah et al [130] 1980 Randomized 35 patients, alcoholic hepatitis All received 3000 kcal 100g protein diet Lower mortality in the study group 18 control 17 study, 70-85 gram of intravenous amino acid Diehl et al [131] [67] 1991 Randomized 39 patients, moderate to severe alcoholic hepatitis 9, standard therapy Improved biochemical parameters 8, oxandrolone + standard therapy 10, PPN 12, oxandrolone + standard therapy + PPN Mezey et al [89] 1991 Randomized 52 patients, alcoholic hepatitis 28 control, dextrose solution No difference in mortality during hospitalization and 2 yr after treatment 26 study, dextrose + amino acid Mendenhall et al [69] 1993 Randomized 273 patients, severe alcoholic hepatitis 136 control No difference in mortality overall 137 study, oxadrolone + enteral nutrition Improvement in mortality in moderately malnourished group(19%) versus control (51%) at 6 mo post treatment Cabre et al [134] 2000 Randomized 71 patients, severe alcoholic hepatitis 36, prednisolone No difference in overall mortality 35, enteral tube 2000 kCal/d
Higher early mortality in nutrition versus higher follow up mortality on steroids Alvarez et al [135] 2004 Case series 13 patients, severe alcoholic hepatitis 13, prednisolone + TEN 2000 kCal/d 15% death during treatment 67% of patients developed infections during treatment -no deaths due to infections designed to replicate treatment effect should be done with treatment dosages and duration that can be employed in the clinical setting. Fur ther modification of scoring systems and streamlining methods to identify patients most likely to respond to treatment continue to improve as we seek to minimize risk of treatment while maximizing survival gain.
At the present, we recommend corticosteroids for patients with alcoholic hepatitis and DF ≥ 32, providing there is not evidence of gastrointestinal bleeding. In patients with active infection, we delay treatment until antibiotic control of infection is achieved. Given the various glucocorticoids and dosages employed in clinical trials, it is difficult to provide clinicians evidence based guidelines on type of glucocorticoid, dosage and length of treatment. We currently recommend using the lowest effective dose of prednisone or prednisolone studied in the literature. As prednisone is less costly, we prescribe prednisone 40 mg daily for up to 28 d. If no improvement in bilirubin is seen after 7 d, we recommend stopping glucocorticoids as suggested by Mathurin [59] ; switching to pentoxifylline is a reasonable alternative in that situation. Although primary treatment with pentoxifylline holds some promise, the evidence of its effi cacy is not as robust as that with steroids.
Although the focus of this article is treatment, preventing the occurrence of disease is important. From physician screening for alcohol abuse to community wide education in a culturally sensitive manner on the risks of alcohol abuse are important health service fi elds. GAHS ≥ 9 predictive of poor prognosis. MELD = 3.8 × loge (bilirubin (mg/dL)) + 1.2 × loge (INR) + 9.6 × loge (creatinine (mg/dL)); One can also calculate the MELD score at the following internet address: www.mayoclinic. org/gi-rst/mayomodel7.html.
APPENDIX A
